AI-generated summary
The authors report a single-center, open-label post-hoc review of 19 patients with early diabetic macular edema treated with multiwavelength photobiomodulation over about three to four weeks. They describe reductions in central retinal thickness and fluid in some patients, stable vision over three months, and no phototoxicity signs up to 16 months. The analysis was uncontrolled and retrospective.
- Participants
- 19
- Who or what was studied
- Patients with early-stage diabetic macular edema and good vision (BCVA better than 20/25) treated in standard clinical care with the Valeda Light Delivery System; 30 eyes in 19 subjects, predominately male, mean age 56 ± 14 years
- Limits stated in the abstract
- Single-center, open-label, post-hoc analysis with no control group, and improvements were reported only in select patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Inflammation, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.